Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Sugary Drinks Linked to Stomach Cancer

Analysis based on 20 articles · First reported Aug 17, 2026 · Last updated Aug 22, 2026

Sentiment
-10
Attention
4
Articles
20
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study may increase consumer awareness and potentially reduce demand for sugary beverages, negatively impacting beverage companies. It could also spur further research and regulatory scrutiny, but immediate market impact is likely limited as the study is observational and requires confirmation.

Beverage Healthcare Food

A large U.S. study published in the journal Gastro Hep Advances found that daily consumption of sugar-sweetened beverages is associated with a more than doubled risk of stomach (gastric) cancer. Researchers from the Mass General Brigham Cancer Institute analyzed data from 112,284 participants in the Nurses Health Study and the Health Professionals Follow-Up Study, identifying 278 cases of gastric cancer over decades of follow-up. After adjusting for other risk factors, those who drank at least one sugary beverage per day had a 2.45 times higher risk compared to those who drank less than one per month. The association was stronger in women, with a 3.04 times higher risk. Higher fructose intake was also linked to increased risk. In contrast, artificially sweetened drinks showed no significant association. The study is observational and cannot prove causation, and the authors note limitations including a predominantly white participant pool and limited data on H. pylori infection and family history. The findings add stomach cancer to the list of cancers previously linked to sugary drinks, including colorectal, breast, and liver cancer. Senior author Andrew T. Chan emphasized that this is the first study to demonstrate such an association in a U.S. population.

10 Andrew T. Chan served as consultant Pfizer
10 Andrew T. Chan served as consultant Boehringer Ingelheim
10 Andrew T. Chan received grant support Freenome
priv
Conducted and published the study, enhancing its reputation in cancer research.
Importance 90.0 Sentiment 10.0
per
Senior author and spokesperson, raising his profile as a gastroenterologist and epidemiologist.
Importance 80.0 Sentiment 10.0
oth
Provided data for the analysis; no direct impact.
Importance 60.0 Sentiment 0.0
oth
Provided data for the analysis; no direct impact.
Importance 60.0 Sentiment 0.0
oth
Published the study, increasing its visibility.
Importance 50.0 Sentiment 0.0
cnt
The study population is U.S.-based, and findings may influence public health recommendations.
Importance 50.0 Sentiment -10.0
oth
Assessed as a potential confounder; no association found with beverage consumption.
Importance 30.0 Sentiment 0.0
stock
Andrew T. Chan served as a consultant; no direct impact.
Importance 10.0 Sentiment 0.0
priv
Andrew T. Chan served as a consultant; no direct impact.
Importance 10.0 Sentiment 0.0
priv
Provided grant support to Andrew T. Chan; no direct impact.
Importance 10.0 Sentiment 0.0
priv
Reported on the study, quoting the senior author.
Importance 10.0 Sentiment 0.0
priv
Reported on the study, providing medical news.
Importance 10.0 Sentiment 0.0
priv
Reported on the study, summarizing findings.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.